GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Price-to-Free-Cash-Flow
中文

Allergy Therapeutics (Allergy Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-25), Allergy Therapeutics's share price is $0.02. Allergy Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.05. Hence, Allergy Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Allergy Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Allergy Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 102.50. The lowest was 8.58. And the median was 32.11.

AGYTF's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 21.73
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Allergy Therapeutics's Free Cash Flow per Share for the six months ended in Dec. 2023 was $-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.05.

During the past 13 years, Allergy Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 66.60% per year. The lowest was -237.00% per year. And the median was 42.60% per year.


Allergy Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Allergy Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Price-to-Free-Cash-Flow Chart

Allergy Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.00 9.33 27.78 - -

Allergy Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Allergy Therapeutics's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allergy Therapeutics's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Price-to-Free-Cash-Flow falls into.



Allergy Therapeutics Price-to-Free-Cash-Flow Calculation

Allergy Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.02/-0.049
=N/A

Allergy Therapeutics's Share Price of today is $0.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Allergy Therapeutics  (OTCPK:AGYTF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Allergy Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (Allergy Therapeutics) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (Allergy Therapeutics) Headlines